These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27139641)

  • 1. 1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal Structure.
    Shaban NM; Shi K; Li M; Aihara H; Harris RS
    J Mol Biol; 2016 Jun; 428(11):2307-2316. PubMed ID: 27139641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain.
    Bohn MF; Shandilya SM; Albin JS; Kouno T; Anderson BD; McDougle RM; Carpenter MA; Rathore A; Evans L; Davis AN; Zhang J; Lu Y; Somasundaran M; Matsuo H; Harris RS; Schiffer CA
    Structure; 2013 Jun; 21(6):1042-50. PubMed ID: 23685212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Insights into HIV-1 Vif-APOBEC3F Interaction.
    Nakashima M; Ode H; Kawamura T; Kitamura S; Naganawa Y; Awazu H; Tsuzuki S; Matsuoka K; Nemoto M; Hachiya A; Sugiura W; Yokomaku Y; Watanabe N; Iwatani Y
    J Virol; 2016 Jan; 90(2):1034-47. PubMed ID: 26537685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.
    Albin JS; Brown WL; Harris RS
    Virology; 2014 Feb; 450-451():49-54. PubMed ID: 24503066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
    Binka M; Ooms M; Steward M; Simon V
    J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins.
    Zhang W; Chen G; Niewiadomska AM; Xu R; Yu XF
    PLoS One; 2008; 3(12):e3963. PubMed ID: 19088851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F.
    Siu KK; Sultana A; Azimi FC; Lee JE
    Nat Commun; 2013; 4():2593. PubMed ID: 24185281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the DNA sequence/length and pH on deaminase activity, as well as the roles of the amino acid residues around the catalytic center of APOBEC3F.
    Wan L; Nagata T; Katahira M
    Phys Chem Chem Phys; 2018 Jan; 20(5):3109-3117. PubMed ID: 28825755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
    Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
    J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Davis RW; York IA; Zheng YH
    J Virol; 2010 Jun; 84(11):5741-50. PubMed ID: 20335268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
    J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Wang X; York IA; Zheng YH
    J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
    Albin JS; Harris RS
    Expert Rev Mol Med; 2010 Jan; 12():e4. PubMed ID: 20096141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV restriction by APOBEC3 in humanized mice.
    Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
    PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches.
    Richards C; Albin JS; Demir Ö; Shaban NM; Luengas EM; Land AM; Anderson BD; Holten JR; Anderson JS; Harki DA; Amaro RE; Harris RS
    Cell Rep; 2015 Dec; 13(9):1781-8. PubMed ID: 26628363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Interactions of a DNA Modifying Enzyme APOBEC3F Catalytic Domain with a Single-Stranded DNA.
    Fang Y; Xiao X; Li SX; Wolfe A; Chen XS
    J Mol Biol; 2018 Jan; 430(1):87-101. PubMed ID: 29191651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.
    Cadima-Couto I; Saraiva N; Santos AC; Goncalves J
    J Neuroimmune Pharmacol; 2011 Jun; 6(2):296-307. PubMed ID: 21279453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.